WASHINGTON, D.C. — The month of February has historically served as a critical juncture for healthcare policy in the United States, but for the metastatic breast cancer (MBC) community, February 2026 has proven to be a transformative period of legislative mobilization and fiscal progress. Spearheaded by METAvivor, a leading non-profit dedicated to funding MBC research and advocacy, the month saw the launch of the third annual GroundSwell Advocacy Event, the passage of significant federal funding increases, and a strategic pivot toward modernizing how cancer data is tracked nationwide.
As the federal government navigates a complex appropriations landscape—marked by both bipartisan successes in healthcare and a localized shutdown within the Department of Homeland Security—METAvivor advocates have successfully positioned MBC priorities at the forefront of the congressional agenda.
Main Facts: A Dual Focus on Funding and Legislative Reform
The advocacy efforts in February were defined by two primary pillars: securing robust federal funding for cancer research and advancing specific pieces of legislation designed to eliminate barriers to care for patients living with terminal illness.
The centerpiece of the month’s grassroots activity was the GroundSwell Virtual Advocacy Event, which officially commenced on February 23. This initiative empowered over 100 advocates from across the country to engage directly with congressional offices. Unlike traditional "Hill Days," GroundSwell utilizes a virtual platform to ensure that patients—many of whom are currently undergoing treatment or face mobility challenges—can participate in the democratic process from their homes.
Simultaneously, the federal landscape shifted significantly with the signing of the Consolidated Appropriations Act of 2026. This massive funding package provided a much-needed boost to the National Institutes of Health (NIH) and the National Cancer Institute (NCI). Notably for the MBC community, the Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP) for breast cancer saw its budget increased to $145 million, a $15 million jump from the previous fiscal year.
On the legislative front, momentum continued to build for the Metastatic Breast Cancer Access to Care Act (H.R. 2048/S. 3442). The bill seeks to waive the five-month waiting period for Social Security Disability Insurance (SSDI) and the subsequent 24-month waiting period for Medicare for individuals diagnosed with MBC. As of late February, the House version of the bill reached a critical milestone of 214 cosponsors, bringing it within striking distance of a floor vote.
Chronology of Key Events: A Month of Legislative Momentum
The trajectory of February’s advocacy can be traced through a series of strategic meetings, legislative deadlines, and grassroots activations.
-
February 3: The Signing of the Consolidated Appropriations Act.
President Trump signed the final negotiated appropriations package for Fiscal Year 2026. This concluded months of debate between the House and Senate, ultimately favoring an increase in medical research spending. This act provided the baseline for the current year’s research grants and established the funding levels for the CDC’s Division of Cancer Prevention and Control. -
February 13: DHS Impasse and Partial Shutdown.
While healthcare funding was secured, a stalemate occurred regarding Department of Homeland Security (DHS) appropriations. Congress failed to reach an agreement by the self-imposed deadline, leading to a shutdown of the Coast Guard, TSA, and Secret Service. However, the MBC advocacy community remained largely unaffected as the "One Big Beautiful Bill" enacted earlier in the year had already secured funding for the NIH and other vital health agencies. -
Mid-February: Strategic Meeting with NAACCR.
METAvivor leadership met with the North American Association of Central Cancer Registries (NAACCR). This meeting was a pivotal step in the organization’s "SEER Strategy," aiming to address the systemic undercounting of metastatic patients in national cancer databases. -
February 23: Launch of GroundSwell.
The third annual GroundSwell event officially launched. Following weeks of "State Captain" training and webinar-based education, advocates began their two-week sprint of virtual meetings with healthcare staffers in the House and Senate. -
Late February: Preparation for FY27.
Even as FY26 funding was finalized, the focus shifted to the next cycle. METAvivor joined the AdHoc Group on Healthcare Funding and One Voice Against Cancer (OVAC) to draft unified requests for the 2027 fiscal year, anticipating the President’s budget release in late March.
Supporting Data: Funding Milestones and Legislative Benchmarks
The impact of METAvivor’s advocacy is most clearly visible in the cold, hard numbers of federal appropriations and legislative cosponsorship.
The Federal Budget Breakdown
The Consolidated Appropriations Act of 2026 reflected a clear recognition of the importance of cancer research. The following data highlights the shift in funding levels:
| Agency/Program | FY25 Funding | FY26 Final Appropriation | Change |
|---|---|---|---|
| DOD Breast Cancer Research | $130 Million | $145 Million | +$15 Million |
| NIH General Funding | Increased | Increased | TBD (Final Tally) |
| ARPA-H | Maintained | Maintained | Level Funding |
The $15 million increase for the DOD program is particularly significant, as this program is known for its high-risk, high-reward research that often focuses specifically on the mechanisms of metastasis, which is the cause of nearly all breast cancer deaths.
Legislative Tracking: Progress on Key Bills
METAvivor’s "Legislative Priorities" document has served as a roadmap for advocates. The progress of these bills in February indicates growing bipartisan support:
- H.R. 2048 (MBC Access to Care Act – House): Gained 17 new cosponsors in February (including 12 Republicans). Total: 214 (154 Democrats, 60 Republicans).
- S. 3442 (MBC Access to Care Act – Senate): Increased from 3 to 5 cosponsors (3 Republicans, 2 Democrats).
- Cancer Drug Parity Act: Currently holds 26 House cosponsors. Efforts are underway to secure a Senate lead for re-introduction.
Official Responses and Strategic Coalitions
The METAvivor Advocacy Team emphasized that their success is rooted in "solidarity with other stakeholders." By joining the AdHoc Group on Healthcare Funding and One Voice Against Cancer (OVAC), METAvivor has amplified its voice, ensuring that the specific needs of the metastatic community are not lost in broader cancer discussions.
In an official update to advocates, the team stated:
"This solidarity with other stakeholders in the patient, provider, and research communities will amplify the voice of our advocates and maximize the impact of our shared funding request. We look forward to the impact that these over 100 advocates will have at this pivotal time in the Congressional session."
Furthermore, METAvivor is taking a sophisticated approach to data through its engagement with the National Cancer Institute’s SEER (Surveillance, Epidemiology, and End Results) Program. The organization’s leadership expressed a commitment to modernizing how cancer registries track recurrence. Currently, many registries only record a patient’s status at initial diagnosis; if a patient’s cancer later metastasizes, that data is often not captured efficiently. METAvivor is working with the Alliance for Breast Cancer Policy to highlight these gaps and demand greater transparency and accuracy in data collection.
Technological and Structural Evolution
Recognizing that effective advocacy requires modern tools, METAvivor’s Advocacy Committee is currently evaluating a transition to Voter Voice, a digital advocacy software. This platform is designed to streamline the process for advocates to contact their representatives and for the organization to track the effectiveness of its outreach.
This move toward a more robust digital infrastructure is part of a broader effort to make advocacy accessible. By identifying "State Captains" and providing scripts, fact sheets, and staff email addresses, METAvivor is lowering the barrier to entry for political engagement. The goal is to create a "grasstops" and "grassroots" hybrid model where seasoned advocates lead the way while new voices are easily integrated into the movement.
Implications for the Metastatic Breast Cancer Community
The developments of February 2026 have profound implications for the 168,000+ Americans living with metastatic breast cancer.
- Financial Relief on the Horizon: The surge in cosponsors for the MBC Access to Care Act suggests that the "waiting period" for benefits may finally be nearing its end. For a patient with a terminal diagnosis, a five-month wait for SSDI and a two-year wait for Medicare is often a wait they cannot afford. Eliminating these barriers would provide immediate financial stability for thousands of families.
- Research Continuity: The $145 million in DOD funding ensures that innovative research projects—those specifically targeting why and how cancer spreads—will continue to receive the necessary capital. This is the only way to move MBC from a terminal diagnosis to a chronic, manageable disease.
- Data-Driven Advocacy: The focus on the SEER registry implies a future where the true burden of MBC is known. If the government can accurately track how many people are living with metastatic disease (rather than just those diagnosed with it de novo), it will be much harder for policymakers to ignore the need for specialized funding and support services.
- A New Model of Virtual Power: The success of the GroundSwell event proves that physical presence on Capitol Hill is no longer the only way to exert influence. This empowers the most vulnerable members of the MBC community to remain active participants in the fight for their lives, regardless of their physical location or health status.
As METAvivor looks toward March and the upcoming "Thriving Together" conference, the momentum generated in February serves as a powerful reminder of the impact of coordinated, data-driven advocacy. With FY27 appropriations requests already in development and the Cancer Drug Parity Act gaining steam, the MBC community is no longer just asking for a seat at the table—they are helping to set the agenda.
Sincerely,
The METAvivor Advocacy Team
About the Author
